These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37193673)

  • 41. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
    Maas BM; Lommerse J; Plock N; Railkar RA; Cheung SYA; Caro L; Chen J; Liu W; Zhang Y; Huang Q; Gao W; Qin L; Meng J; Witjes H; Schindler E; Guiastrennec B; Bellanti F; Spellman DS; Roadcap B; Kalinova M; Fok-Seang J; Catchpole AP; Espeseth AS; Stoch SA; Lai E; Vora KA; Aliprantis AO; Sachs JR
    EBioMedicine; 2021 Nov; 73():103651. PubMed ID: 34775220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody development for preventing the human respiratory syncytial virus pathology.
    Soto JA; Gálvez NMS; Pacheco GA; Bueno SM; Kalergis AM
    Mol Med; 2020 Apr; 26(1):35. PubMed ID: 32303184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-Acting RSV Antibody Injection Protects Healthy Infants.
    Slomski A
    JAMA; 2022 Apr; 327(16):1539. PubMed ID: 35471514
    [No Abstract]   [Full Text] [Related]  

  • 46. [-Prevention of respiratory syncytial virus infection-].
    Gillet Y
    Arch Pediatr; 1998 Mar; 5(3):333-7. PubMed ID: 10328005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.
    Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Respiratory syncytial virus immunisation overview.
    Foley DA; Phuong LK; Englund JA
    J Paediatr Child Health; 2020 Dec; 56(12):1865-1867. PubMed ID: 33089944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
    Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.
    Robbins JM; Tilford JM; Jacobs RF; Wheeler JG; Gillaspy SR; Schutze GE
    Arch Pediatr Adolesc Med; 1998 Apr; 152(4):358-66. PubMed ID: 9559712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation.
    Chan PW; Abdel-Latif ME
    Acta Paediatr; 2003 Apr; 92(4):481-5. PubMed ID: 12801117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.
    Vekemans J; Moorthy V; Giersing B; Friede M; Hombach J; Arora N; Modjarrad K; Smith PG; Karron R; Graham B; Kaslow DC
    Vaccine; 2019 Nov; 37(50):7394-7395. PubMed ID: 29395536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.
    Jones BG; Sealy RE; Surman SL; Portner A; Russell CJ; Slobod KS; Dormitzer PR; DeVincenzo J; Hurwitz JL
    Vaccine; 2014 May; 32(26):3264-73. PubMed ID: 24721531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.
    Corbeil S; Seguin C; Trudel M
    Vaccine; 1996 Apr; 14(6):521-5. PubMed ID: 8782350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Strategies and recommendations to face respiratory syncytial virus disease in 2024].
    Paris E; Daza P; Tapia L; Díaz JP; Cruces Romero P; Castillo A; González C; Endeiza ML; Jofré L; Castro F; Zamorano A; Rodríguez J; Acevedo J; Santa Cruz T; González J; Escárate R; Moreno JP; Cisternas P
    Andes Pediatr; 2024 Feb; 95(1):17-23. PubMed ID: 38587340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
    J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.